Scientists in Israel have just engineered a tobacco plant to grow five psychedelic drugs at once. They call it pharmaceutical progress. They call it a simpler, more sustainable route to medicine. Yet what they have actually built, beneath the language of research and therapeutic potential, is a more efficient delivery system for psychotropic compounds that have already demonstrated, repeatedly and on the record, that they harm people. This is where psychedelic drug research has arrived. Not at a cure. At a crop.
The five compounds produced by the modified tobacco plant are psilocybin and psilocin, found in magic mushrooms; DMT, extracted from various plants; and bufotenin and 5-methoxy-DMT, secreted by the Colorado river toad. Using a technique called agroinfiltration, researcher Asaph Aharoni and his team at the Weizmann Institute introduced nine foreign genes into a single tobacco plant and produced all five simultaneously. Furthermore, Aharoni confirmed that the same process could be applied to tomato, potato and corn.
He chose not to make the modification permanent. When asked why, he said it would be “a little bit tricky” because people would ask for seeds.
Read that again. The lead scientist on a project that others present as medical advancement describes his primary reason for restraint as the inconvenience of people asking for seeds. This is not pharmaceutical development. Instead, this is cultivation of some of the most powerful mind-altering substances on earth, with a voluntary handbrake that nobody is required to keep applied.
What the Evidence Actually Says
Before researchers harvest a single tobacco plant, it is worth asking what the therapeutic case for these compounds actually looks like. Because psychedelic drug research has been telling the same story for years: breakthrough treatment, revolutionary potential, the dawn of a new era in mental health. Yet the evidence has never caught up with the narrative.
Notably, the largest comparison trial of psilocybin ever conducted enrolled just 59 people. Earlier studies ran on 12 to 27 participants, some with no control group at all. These are not the foundations of proven medicine. Rather, they are the foundations of a billion-dollar industry that decided momentum was more important than proof.
The conflicts of interest run deep. One leading psychedelic drug researcher acknowledged knowing only a single colleague who had never personally used the drugs being studied. Moreover, financial ties between researchers and the psychedelic companies funding them appear disclosed in paper after paper. The field has a term for this kind of research: “me-search.” Research that finds what it was always going to find because the people running it already believe the answer.
Although the surge of investment and media attention surrounding psychedelic-assisted therapy has been enormous, the quality of the science has not kept pace. Growing scepticism has been building within the scientific community itself, not from outside critics, but from researchers who have looked closely at the evidence and found it wanting. It has simply attracted more investment and more media attention.
The Brain Studies Say “Shaky Ground”
In April 2026, researchers published the most comprehensive study of psychedelic drugs and the brain ever conducted in Nature Medicine. The study drew on more than 500 brain scans, 267 participants, eleven independent studies, and five substances, including three of the five now grown in an Israeli greenhouse. Researchers found that all five flatten the brain’s natural processing hierarchy, dissolving the organised structure through which the brain normally functions and producing what they called “unleashed cross-talk between brain systems.”
Journalists widely reported this as a landmark finding. However, what received far less coverage was what the study’s senior author said about the state of his own field: “This field is emerging, and it is very important, but they are on shaky ground.”
Additionally, the study’s own rigorous modelling found that earlier, smaller studies claiming widespread brain disintegration under psychedelics did not hold up. For context, the DMT dataset, covering one of the five compounds now cultivated in that tobacco plant, comprised only 16 participants. The ayahuasca dataset comprised just nine. Yet these are the numbers researchers use to justify scaling production.
Shaky ground is not a metaphor here. It is the senior researcher’s own description. Consequently, the response from the laboratory is to build a greenhouse.
The Placebo Problem Nobody Wants to Name
A fundamental flaw sits at the heart of psychedelic-assisted therapy trials that the industry does not advertise. Researchers cannot blind these studies. Participants always know whether they have taken a psychedelic drug, because the effects are unmistakable. As a result, every trial result carries contamination by expectation. People who believe they receive a powerful treatment often feel better simply because they believe it. People who realise they received a placebo sometimes deteriorate sharply from the disappointment.
Researchers at the University of Auckland and King’s College London have both published work on this problem. Their conclusion is stark: the large differences between treatment and placebo groups in psychedelic drug research trials likely measure more than just improvement in the treated group. In fact, they also measure deterioration in the placebo group. Consequently, the results are inflated, and the industry is overstating the effectiveness of these drugs. Meanwhile, the tobacco plant is being engineered to grow more of them.
The People Nobody Mentions
Behind all the trial data and the brain scans and the greenhouse engineering, there are people. They tend not to appear in the press releases.
Kate Hyatt was 32 years old. In June 2021 she attended a plant medicine retreat in Worcestershire and took a powerful hallucinogen. Three months later she described a psychotic break so severe she felt her brain was going to explode. That autumn she took her own life. The coroner linked her deteriorating symptoms to the hallucinogens she had consumed. She had gone looking for help with her mental health. The psychedelic-assisted therapy movement gave her something that destroyed it.
She is not alone. A Compass Pathways clinical trial of psilocybin for treatment-resistant depression reported that three participants showed suicidal behaviour lasting at least a month after receiving the drug. Furthermore, a 21-year-old woman who self-medicated with a high dose of psilocybin to treat her own depression walked to the middle of the Golden Gate Bridge and jumped. In MAPS-sponsored MDMA therapy trials, footage emerged of therapists restraining a patient, gagging her and lying on top of her while she was under the influence of the compound. The lead therapist later admitted to having sex with her while she remained enrolled in the trial.
These are not aberrations. Rather, they are the logical consequence of administering compounds that, by the admission of researchers in the field, make users “pliant and suggestible.” When a substance dissolves the brain’s normal defences and places a vulnerable person in the hands of anyone with less-than-honourable intentions, the outcome is not always therapeutic. Sometimes it is devastating. No tobacco plant, however efficiently engineered, changes that pharmacological reality.
Science Racing Ahead of Ethical Reckoning
There is a word for what happens when scientific capability races ahead of ethical reckoning. The Weizmann Institute has demonstrated that five psychotropic compounds can grow in a single crop, at agricultural scale, using a process transferable to the most common food plants on earth. They have done this in a field where the therapeutic evidence sits on shaky ground by the admission of its own senior researchers, where documented harms include deaths, suicidal behaviour within clinical trials and sexual abuse within supervised therapy sessions, and where a scientist’s reluctance to deal with seed requests stands as the primary restraint against open distribution.
The creature, to borrow Mary Shelley’s framing, is not being built because medicine needs it. Instead, the laboratory builds it because the capital is there, and because a field that has never allowed evidence to slow its momentum now has a cultivation method that grows in soil, requires no pharmaceutical supply chain and can scale without limit.
Rupert Fray at the University of Nottingham called it a valuable technical accomplishment and spoke of “green factories” growing compounds in greenhouses. He is right about the factories. However, the question his framing avoids is what these factories are actually producing, and for whom.
This Is Not Medicine. This Is Access.
Psychedelic drug research has not yet established what these compounds treat, in whom they are safe, at what dose, under what supervision or with what long-term consequences. Its own most rigorous brain study describes its foundations as shaky. Its own researchers acknowledge the conflicts of interest. Moreover, its own clinical trials have produced documented suicidal behaviour and enabled abuse.
What it has established, reliably and at scale, is an appetite. An appetite in an industry, in a media cycle and in a culture that has decided these substances are the next frontier, and that the science can catch up later. Therefore, the tobacco plant is not the beginning of responsible pharmaceutical development. It is the next step in a process that has never been primarily about medicine.
The lead researcher noted that people will ask for seeds. He is correct. They will. And when they do, the question of whether psychedelic drug research ever delivered on its therapeutic promise will feel very distant from the reality of what was grown, and where it ended up.
(Source: WRD News)